St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections more

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones

SAN ANTONIO--(BUSINESS WIRE)--ViroXis Corporation today announced that the final patient has completed treatment in its Phase 2 clinical study of the Company’s East Indian Sandalwood Oil (EISO) based therapy for HPV/common skin warts. Efficacy and safety results will be known once the data is analyzed in April following a three-month follow-up period.

A total of 183 patients have completed enrollment and the products have been very well tolerated with very few adverse events reported. In a prior Investigator-sponsored clinical study of EISO to treat patients with HPV/common warts (including pediatric patients), EISO was very well tolerated and demonstrated significant efficacy results over placebo. The Company hopes to confirm these initial results in this larger four-arm, double-blind, placebo controlled Phase 2 trial.

ViroXis also announced plans to initiate a second Phase 2 clinical study in a new indication, Molluscum contagiosum (MCV), in a pediatric population. MCV is a very prevalent, highly contagious pox virus skin infection for which there are currently no approved prescription treatments. A small preliminary study of EISO in MCV patients (including pediatric patients) was completed, and it was found that EISO was effective and very well tolerated. For the Company's four-arm, double-blind, placebo controlled MCV study, a proprietary cream was developed to complement the ointment formulation being used in the HPV trial.

“ViroXis has quickly emerged as leader in the development of botanical drug products, a new and important group of drug candidates afforded a distinct approval process by the FDA. We are developing EISO to treat highly prevalent viral skin conditions in both adults and children, for which there are currently no approved prescription products,” said Ian Clements, Chief Executive Officer of ViroXis Corporation.

About ViroXis
ViroXis' mission is to develop and commercialize novel, safe and effective prescription and over-the-counter botanical products for the treatment of virally-induced skin conditions. Botanically-derived drugs have formed the backbone of the pharmaceutical industry and the 2004 FDA botanical drug development guidelines aim to streamline the approval of drugs, such as ViroXis' lead drug candidate, that are traditional plant-derived mixtures rather than a single chemical entity, and that have a historical record of safe human use. ViroXis’ EISO-based drug candidates are sourced under an exclusive long-term supply agreement from TFS Corporation, Ltd. of Australia (ASX: TFC). TFS manages the world’s largest commercial, sustainable plantations of East Indian sandalwood trees and is the only supplier qualified by ViroXis to meet the requirements as an EISO botanical drug substance supplier.

Contacts
ViroXis Corporation
Ian Clements, CEO, 210-399-2315
ian@viroxis.com back

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more